Prognostic Value of CD74 and HLA-DR Expressions in Invasive Ductal Breast Cancer
Advances in Breast Cancer Research (ABCR)
i.e. patients’ demographics, pathology results, and treatment characteristics) were
included in the study. Paraffin blocks of tumor specimens were re-examined with
immunohistochemical methods in March 2010 to determine the extent of CD74 and
HLA-DR expression and the level of tumor infiltrating lymphocyte (TILs).
Results: The mean age and the median duration of follow-up for the 41
participants were 48.29 ± 11.86 years and 125 months (range 115 to 135 months),
respectively. Disease-free survival (DFS) in CD74 negative subjects was better
than in CD74 positive patients, but the difference was not statistically
significant (p = 0.75). Similarly, HLA-DR negative and HLA-DR positive groups
showed no statistically significant differences in terms of DFS (p = 0.81).
Conclusion: There were positive but insignificant correlations with increased
expression of CD74, decreased expression of HLA-DR, and TILs levels. Further
studies involving larger sample sizes may provide more insight into these